• Wed news: BioNTech buying Biotheus. FDA’s Califf lists hopes for his successor. Amgen loses $12B market cap from hidden spreadsheet tab. TRex Bio raises $84M. London is Europe’s life science capitol. See more on our front page

Uncertainty of 2022





Anyone who hung around for this was foolish. I left with disappointment about the plight of Adu.

To call someone foolish for staying yet you worked here is the kettle calling the pot black. You are more of a fool if your story is even real. You continue to troll this site yet you have moved on with another company. Who are you trying to kid? Many people have stayed because they do not plan on paying their sign-on back.
 












To call someone foolish for staying yet you worked here is the kettle calling the pot black. You are more of a fool if your story is even real. You continue to troll this site yet you have moved on with another company. Who are you trying to kid? Many people have stayed because they do not plan on paying their sign-on back.
You are correct. I stayed beyond a year to avoid the payback. However, a majority of the Adu sales force has been around more than a year. That was August of 2021. Kind of foolish.